The continuing complexities of high-density lipoprotein metabolism in drug discovery and development

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 9, 2007, Pages 1133-1136

  Suckling, Keith ^a  

^a NONE   (United Kingdom)

Author keywords

Atherosclerosis; CETP inhibitor; HDL; Imaging; Niacin; Torcetrapib

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; FARNESOID X RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR STIMULATING AGENT; LIPID; LIVER X RECEPTOR AGONIST; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TORCETRAPIB; UNCLASSIFIED DRUG; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVATIVE;

ATHEROSCLEROSIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG ACTIVITY; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; LIPOPROTEIN METABOLISM; MORTALITY; NONHUMAN; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; PHASE 3 CLINICAL TRIAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS, PHASE III; DRUG DESIGN; HUMANS; LIPOPROTEINS, HDL; NIACIN; QUINOLINES;

EID: 34548825124     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.9.1133     Document Type: Editorial

References (21)

1. BANSAL S, BURING JE, RIFAI N, MORA S, SACKS FM, RIDKER PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 298:309-316.
2. NORDESTGAARD BG, BENN M, SCHNOHR P, TYBJAERG-HANSEN A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA (2007) 298:299-308.
3. ANSELL BJ, FONAROW GC, FOGELMAN AM: The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. (2007) 18:427-434.
4. CHAPMAN MJ: Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. (2006) 111:893-908.
5. TALL AR, YVAN-CHARVET L, WANG N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. (2007) 27:257-260.
6. NICHOLLS SJ, SIPAHI I, SCHOENHAGEN P, CROWE T, TUZCU EM, NISSEN SE: Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat. Rev. Drug Discov. (2006) 5:485-492.
7. SUCKLING KE: Discontinued drugs in 2005: cardiovascular drugs. Expert Opin. Investig. Drugs (2006) 15:1299-1308.
8. NISSEN SE, TARDIF JC, NICHOLLS SJ et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. (2007) 356:1304-1316.
9. KASTELEIN JJP, VAN LEUVEN SI, BURGESS L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. (2007) 356:1620-1630.
10. CORTI R: Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy. Pharmacol. Ther. (2006) 110:57-70.
11. REVKIN JH, SHEAR CL, POULEUR HG, RYDER SW, ORLOFF DG: Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. Pharmacol. Rev. (2007) 59:40-53.
12. GERVOIS P, FRUCHART J-C, STAELS B: Drug insight mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Practice Endocrinol. Metab. (2007) 3:145-156.
13. BROWN JD, PLUTZKY J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation (2007) 115:518-533.
14. KUIPERS F, STROEVE JH, CARON S, STAELS B: Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. (2007) 18:289-297.
15. GEYEREGGERR, ZEYDA M, STULNIG TM: Liver X receptors in cardiovascular and metabolic disease. Cell Mol. Life Sci. (2006) 63:524-539.
16. NAIK SU, WANG X, DA SILVA JS et al.: Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2006) 113:90-97.
17. NICHOLLS SJ, NISSEN SE: New targets of high-density lipoprotein therapy. Curr. Opin. Lipidol. (2007) 18:421-426.
18. SUCKLING KE: The ideal model in atherosclerosis and dyslipidaemia - does it exist? Expert Opin. Drug Discov. (2007) 1:507-511.
19. GUYTON JR: Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr. Opin. Lipidol. (2007) 18:415-420.
20. TARDIF JC, GREGOIRE J, L'ALLIER PL et al.: Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 297:1675-1682.
21. PACKARD C: A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atheroscler. Suppl. (2006) 7:21-29.